Literature DB >> 12393683

Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays.

Juan F García1, Francisca I Camacho, Manuel Morente, Máximo Fraga, Carlos Montalbán, Tomás Alvaro, Carmen Bellas, Angel Castaño, Ana Díez, Teresa Flores, Carmen Martin, Miguel A Martinez, Francisco Mazorra, Javier Menárguez, Maria J Mestre, Manuela Mollejo, Ana I Sáez, Lydia Sánchez, Miguel A Piris.   

Abstract

Tumoral cells in Hodgkin lymphoma (HL) display an increased growth fraction and diminished apoptosis, implying a profound disturbance of the cell cycle and apoptosis regulation. However, limitations of molecular techniques have prevented the analysis of the tumor suppressor pathways and cell-cycle checkpoints. Tissue microarray (TMA) is a powerful tool for analyzing a large number of molecular variables in a large series of tumors, although the feasibility of this technique has not yet been demonstrated in heterogeneous tumors. The expression of 29 genes regulating the cell cycle and apoptosis were analyzed by immunohistochemistry and in situ hybridization in 288 HL biopsies using TMA. The sensitivity of the technique was validated by comparing the results with those obtained in standard tissue sections. The results revealed multiple alterations in different pathways and checkpoints, including G1/S and G2/M transition and apoptosis. Striking findings were the overexpression of cyclin E, CDK2, CDK6, STAT3, Hdm2, Bcl2, Bcl-X(L), survivin, and NF-kappaB proteins. A multiparametric analysis identified proteins associated with increased growth fraction (Hdm2, p53, p21, Rb, cyclins A, B1, D3, and E, CDK2, CDK6, SKP2, Bcl-X(L), survivin, STAT1, and STAT3), and proteins associated with apoptosis (NF-kappaB, STAT1, and RB). The analysis also demonstrated that Epstein-Barr virus (EBV)-positive cases displayed a characteristic profile, confirming the pathogenic role of EBV in HL. Survival probability depends on multiple biologic factors, including overexpression of Bcl2, p53, Bax, Bcl-X(L), MIB1, and apoptotic index. In conclusion, Hodgkin and Reed-Sternberg cells harbor concurrent and overlapping alterations in the major tumor suppressor pathways and cell-cycle checkpoints. This appears to determine the viability of the tumoral cells and the clinical outcome.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12393683     DOI: 10.1182/blood-2002-04-1128

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  49 in total

1.  Immunoexpression of Survivin in non-neoplastic lymphoid tissues and malignant lymphomas using a new monoclonal antibody reactive on paraffin sections.

Authors:  José Vassallo; Talal Al Saati; Randy D Gascoyne; Kathyrn Welsh; John C Reed; Pierre Brousset; Georges Delsol
Journal:  J Hematop       Date:  2010-01-30       Impact factor: 0.196

2.  Expression of Survivin in pancreatic cancer and its correlation to expression of Bcl-2.

Authors:  Jian-Guo Qiao; Yu-Qing Zhang; Yu-Chun Yin; Zui Tan
Journal:  World J Gastroenterol       Date:  2004-09-15       Impact factor: 5.742

Review 3.  Reappraisal of BCL3 as a molecular marker of anaplastic large cell lymphoma.

Authors:  Hitoshi Ohno; Momoko Nishikori; Yoshitomo Maesako; Hironori Haga
Journal:  Int J Hematol       Date:  2005-12       Impact factor: 2.490

4.  Advances in cancer tissue microarray technology: Towards improved understanding and diagnostics.

Authors:  Wenjin Chen; David J Foran
Journal:  Anal Chim Acta       Date:  2006-01-23       Impact factor: 6.558

5.  SCFSkp2 complex targeted by Epstein-Barr virus essential nuclear antigen.

Authors:  Jason S Knight; Nikhil Sharma; Erle S Robertson
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

6.  Quantification of diverse subcellular immunohistochemical markers with clinicobiological relevancies: validation of a new computer-assisted image analysis procedure.

Authors:  Marylène Lejeune; Joaquín Jaén; Lluis Pons; Carlos López; Maria-Teresa Salvadó; Ramón Bosch; Marcial García; Patricia Escrivà; Jordi Baucells; Xavier Cugat; Tomás Alvaro
Journal:  J Anat       Date:  2008-06       Impact factor: 2.610

7.  Ductal adenocarcinoma of the pancreas: Expression of growth factor receptors, oncogenes and suppressor genes, and their relationship to pathological features, staging and survival.

Authors:  Antonio Lozano-Leon; Begona Vieites Perez-Quintela; Julio Iglesias-García; Jose Lariño-Noia; Evaristo Varo; Jeronimo Forteza; J Enrique Domínguez-Muñoz
Journal:  Oncol Lett       Date:  2010-11-23       Impact factor: 2.967

8.  NF-kappaB/STAT3/PI3K signaling crosstalk in iMyc E mu B lymphoma.

Authors:  Seong-Su Han; Hwakyung Yun; Dong-Ju Son; Van S Tompkins; Liangping Peng; Seung-Tae Chung; Joong-Su Kim; Eun-Sung Park; Siegfried Janz
Journal:  Mol Cancer       Date:  2010-04-30       Impact factor: 27.401

9.  Prognostic significance of new immunohistochemical markers in refractory classical Hodgkin lymphoma: a study of 59 cases.

Authors:  Danielle Canioni; Bénédicte Deau-Fischer; Pierre Taupin; Vincent Ribrag; Richard Delarue; Jacques Bosq; Marie-Thérèse Rubio; Damien Roux; Viorel Vasiliu; Bruno Varet; Nicole Brousse; Olivier Hermine
Journal:  PLoS One       Date:  2009-07-22       Impact factor: 3.240

10.  Securin promotes the identification of favourable outcome in invasive breast cancer.

Authors:  K Talvinen; H Karra; S Hurme; M Nykänen; A Nieminen; J Anttinen; T Kuopio; P Kronqvist
Journal:  Br J Cancer       Date:  2009-08-18       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.